---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-187190"
form_type: "8-K"
ticker: "SPRO"
cik: "0001701108"
company_name: "Spero Therapeutics, Inc."
filed_at: "2022-07-01T23:59:59+00:00"
generated_at: "2026-06-24T21:44:01.834335+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Spero Therapeutics grants CEO $254K cash + $508K RSU, CFO $168K cash + $336K RSU retention awards

## Summary
- CEO Ankit Mahadevia receives $254K cash bonus (Nov 30, 2022) and up to $508K in stock based on performance criteria.
- CFO Satyavrat Shukla receives $168K cash bonus (Nov 30, 2022) and up to $336K in stock based on performance criteria.
- Awards tied to continued employment through May 31, 2023 and achievement of pipeline, BD, and financial stewardship goals.
- Unvested RSUs lapse if performance criteria not met by May 31, 2023; vesting acceleration only in certain change-in-control events.

## SEC filing metadata
- accession: 0001193125-22-187190
- form_type: 8-K
- ticker: SPRO
- cik: 0001701108
- company_name: Spero Therapeutics, Inc.
- filed_at: 2022-07-01T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1701108/000119312522187190/0001193125-22-187190-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1701108/000119312522187190/d726728d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-187190
- JSON: https://secwatch.observer/filing/0001193125-22-187190.json
- Plain text: https://secwatch.observer/filing/0001193125-22-187190.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.